Oncolytic viruses for cancer immunotherapy
2020 · Journal of Hematology & Oncology · 334 citations
https://doi.org/10.1186/s13045-020-00922-1
O
Otto Hemminki
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
115
Papers
2.1K
Citations
23
h-index
47
i10-index
Otto Hemminki is an academic researcher from University of Helsinki. The author has contributed to research in topics: Virus-based gene therapy research & CAR-T cell therapy research & Bladder and Urothelial Cancer Treatments. The author has an h-index of 23, co-authored 98 publications.
ORCID: 0000-0002-3396-2391Papers by this author
worksAd3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer
2012 · Molecular Therapy · 85 citations
https://doi.org/10.1038/mt.2012.115
Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM‐CSF: <scp>R</scp>esults <i>in vitro</i>, in rodents and in humans
2015 · International Journal of Cancer · 56 citations
https://doi.org/10.1002/ijc.29536
Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus
2011 · Molecular Therapy · 53 citations
https://doi.org/10.1038/mt.2011.144
Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not
2020 · European Urology Open Science · 14 citations
https://doi.org/10.1016/j.euros.2020.11.003
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine
2024 · Molecular Therapy · 14 citations
https://doi.org/10.1016/j.ymthe.2024.06.029
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat